Technology
For Better Delivery To and Through the Skin
INVISICARE
DRUG DELIVERY TECHNOLOGY
Invisicare® is a patented polymer technology that enhances topical and transdermal drug delivery with controlled release, superior skin adhesion, and improved efficacy—without patches or encapsulation.
- Controlled Release: Delivers active ingredients steadily without initial burst effect
- Superior Skin Adhesion: Improves contact time and effectiveness
- Enhanced Efficacy: Maximizes therapeutic outcomes
- Combines hydrophilic and hydrophobic polymers
- Functions as a complex, not a compound
- Maintains the same toxicity profile as its components
- Uses only GRAS (Generally Recognized As Safe) ingredients
- For transdermal applications, includes proprietary permeation enhancers
- Protected by patents and trade secrets
- Provides licensees with exclusive market differentiation
- Customizable for specific active ingredients and release profiles
- Controlled Release
& Enhanced Absorption - Superior Skin Adhesion
& Non-Occlusive Barrier - Patent-Protected
& Market-Differentiating
Invisicare
polymers
Invisicare is a complex rather than a compound, with the final composition maintaining the same toxicity profile as its components; which are all commonly used or considered GRAS. For transdermal formulations, a proprietary combination of permeation enhancers is incorporated into the solution to get the desired penetration. No mechanical penetration enhancers are used.
Invisicare is available in a series of formulations which are specifically customized for each active ingredient and the type of desired active ingredient release.
Our proprietary polymer technology transforms how active ingredients interact with skin. Through advanced binding mechanisms, Invisicare enhances topical and transdermal drug delivery in three powerful ways:
Maximizes Active Ingredient Release
To achieve optimal delivery of therapeutic compounds. For topical treatments, Invisicare creates a sustained release directly to the target area. For transdermal applications, it enables efficient penetration through dermal layers into systemic circulation without the use of a patch or needles.
Superior Skin Adhesion
As our unique polymer matrix creates a specialized bond with the skin, ensuring consistent product coverage and performance. Products are non-occlusive, forming a protective barrier which still allows for normal skin respiration and perspiration. The “invisible” polymer compositions wear off as part of the natural exfoliation process of the skin’s outer layer cells.
Enhanced Treatment Outcomes
By improving efficacy, safety, patient satisfaction and product performance.
- Safe & Non-Toxic
- Advanced Penetration Without Mechanical Enhancers
- Customized Formulations
TRANSDERMAL DELIVERY
NO PATCH | NO NEEDLES | NO TOXIC PENETRATORS
The INVISICARE Transdermal Advantage
Our advanced Invisicare delivery system transforms drugs that traditionally required pills or injections into simple-to-use topical applications, revolutionizing patient treatment:
- Bypasses liver metabolism, avoiding many side-effects
- Potentially increasing bioavailability of the active
- Delivers steady, controlled drug release
- Avoids digestive system interaction
- Offers non-invasive alternative to injections
Patient-Centric Benefits
Invisicare's transdermal delivery provides a better treatment experience:
- Non-invasive; no needles, no patch required
- Simple application process
- Consistent drug levels
- Improved treatment adherence
- Enhanced therapeutic outcomes
Ongoing Research & Independent Validation
The Company conducts in-house research, development and testing of its Invisicare polymer delivery vehicles, and the products formulated with Invisicare. In addition, where appropriate for validation and independent verification of marketing claims, it utilizes FDA registered independent laboratories with extensive qualifications for carrying out investigative product studies.
News
Releases
Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
